Mega Lifesciences Public Company Limited (MEGA-R) — Cash Flow-to-Debt Ratio
Mega Lifesciences Public Company Limited (MEGA-R) has a Cash Flow-to-Debt Ratio of 0.11x as of June 2025, meaning its operating cash flow of ฿461.26 Million could theoretically repay 0% of its total liabilities (฿4.37 Billion) in one year. See MEGA-R cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mega Lifesciences Public Company Limited Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Mega Lifesciences Public Company Limited across 14 annual periods. Also explore MEGA-R net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Mega Lifesciences Public Company Limited (2011–2024)
Year-by-year debt coverage analysis for Mega Lifesciences Public Company Limited. For market capitalisation and broader financial context, see Mega Lifesciences Public Company Limited (MEGA-R) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (THB) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | ฿2.40 Billion | ฿4.33 Billion | ▲ +50.1% |
| 2023 | 0.37x | ฿1.93 Billion | ฿5.22 Billion | ▲ +8.6% |
| 2022 | 0.34x | ฿2.00 Billion | ฿5.87 Billion | ▼ -34.6% |
| 2021 | 0.52x | ฿2.73 Billion | ฿5.25 Billion | ▲ +47.1% |
| 2020 | 0.35x | ฿1.63 Billion | ฿4.61 Billion | ▲ +3.0% |
| 2019 | 0.34x | ฿1.50 Billion | ฿4.36 Billion | ▲ +45.9% |
| 2018 | 0.24x | ฿919.36 Million | ฿3.91 Billion | ▼ -11.8% |
| 2017 | 0.27x | ฿927.00 Million | ฿3.48 Billion | ▼ -31.0% |
| 2016 | 0.39x | ฿1.26 Billion | ฿3.26 Billion | ▲ +108.0% |
| 2015 | 0.19x | ฿609.12 Million | ฿3.28 Billion | ▼ -17.0% |
| 2014 | 0.22x | ฿614.22 Million | ฿2.74 Billion | ▲ +36.6% |
| 2013 | 0.16x | ฿465.77 Million | ฿2.84 Billion | ▲ +20.2% |
| 2012 | 0.14x | ฿342.02 Million | ฿2.51 Billion | ▲ +0.8% |
| 2011 | 0.14x | ฿266.67 Million | ฿1.97 Billion | — |